Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
-
A3381 EdoxabanTarget: Factor XaSummary: Factor Xa inhibitor
-
A3655 NesbuvirTarget: Nonstructural protein 5B (NS5B)Summary: NS5B polymerase inhibitor
-
A3690 OtamixabanTarget: Factor XaSummary: Direct factor Xa inhibitors,potent and selective
-
A3791 Saquinavir mesylateSummary: HIV Protease Inhibitor
-
A3865 Teneligliptin hydrobromideTarget: DPP-4Summary: Dipeptidyl peptidase-4 inhibitor
-
A4068 SNX-21121 CitationSummary: Hsp90 inhibitor,ATP-competitve,potent and selective
-
A4070 Elvitegravir (GS-9137)Target: HIV IntegrasesSummary: HIV-1 integrase inhibitor,potent
-
A4071 Fluorouracil (Adrucil)3 CitationTarget: Thymidylate SynthaseSummary: Antitumor agent;inhibitor of thymidylate synthase
-
A4073 Raltegravir (MK-0518)1 CitationTarget: integraseSummary: HIV-1 integrase inhibitor
-
A4077 BIBR 953 (Dabigatran, Pradaxa)Summary: Thrombin inhibitor,potent,reversible and direct